Enhanced metabolic regulation consistency
Size:60 capsules
The concern regarding an early increase in risk was most prominently highlighted by the SUSTAIN-6 trial, which found that patients undergoing semaglutide treatment exhibited an elevated risk of diabetic retinopathy complications [82]
However, consumers primary reason for taking a GLP-1 was split between: Treating a chronic health condition (38%) Losing weight (30%) Both losing weight and treating a chronic condition (32%) Why it matters: Consumer awareness and interest is growing in GLP-1s, which is increasing alongside actual use
Being organised can reduce anxiety and make the process smoother
The class includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro, a dual GLP-1/GIP receptor agonist), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Adlyxin)